| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 22 | 2021 | 365 | 4.180 |
Why?
|
| Natural Language Processing | 2 | 2023 | 37 | 1.610 |
Why?
|
| Medical Oncology | 6 | 2022 | 350 | 1.380 |
Why?
|
| Neoplasms | 12 | 2023 | 2809 | 1.290 |
Why?
|
| Medical Informatics | 4 | 2021 | 43 | 1.250 |
Why?
|
| Electronic Health Records | 4 | 2019 | 308 | 1.130 |
Why?
|
| Databases, Factual | 5 | 2022 | 792 | 1.120 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2015 | 367 | 0.960 |
Why?
|
| Software | 4 | 2019 | 647 | 0.930 |
Why?
|
| Pathology, Molecular | 2 | 2019 | 34 | 0.880 |
Why?
|
| Leukemia | 1 | 2023 | 317 | 0.800 |
Why?
|
| Child | 25 | 2023 | 6776 | 0.800 |
Why?
|
| Research Report | 2 | 2021 | 45 | 0.760 |
Why?
|
| Heuristics | 1 | 2019 | 14 | 0.720 |
Why?
|
| Radionuclide Imaging | 2 | 2021 | 217 | 0.710 |
Why?
|
| Pediatrics | 3 | 2021 | 342 | 0.690 |
Why?
|
| Clinical Trials as Topic | 2 | 2023 | 1160 | 0.630 |
Why?
|
| Gene Expression Profiling | 3 | 2013 | 1363 | 0.610 |
Why?
|
| Hospital Units | 1 | 2016 | 30 | 0.600 |
Why?
|
| Biomedical Research | 2 | 2021 | 366 | 0.600 |
Why?
|
| Emergencies | 1 | 2016 | 109 | 0.580 |
Why?
|
| Management Information Systems | 1 | 2016 | 3 | 0.580 |
Why?
|
| Biomarkers, Tumor | 5 | 2022 | 1450 | 0.570 |
Why?
|
| Telemedicine | 1 | 2018 | 159 | 0.570 |
Why?
|
| Patient Transfer | 1 | 2016 | 91 | 0.560 |
Why?
|
| Pressure Ulcer | 1 | 2016 | 43 | 0.550 |
Why?
|
| Humans | 59 | 2023 | 84485 | 0.520 |
Why?
|
| Infant | 15 | 2022 | 3003 | 0.510 |
Why?
|
| Polysaccharides | 1 | 2015 | 88 | 0.510 |
Why?
|
| Patient Care Team | 1 | 2016 | 273 | 0.510 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 658 | 0.480 |
Why?
|
| Critical Care | 1 | 2016 | 359 | 0.480 |
Why?
|
| Paired Box Transcription Factors | 1 | 2013 | 50 | 0.480 |
Why?
|
| Heart Arrest | 1 | 2016 | 263 | 0.470 |
Why?
|
| Lysine | 2 | 2011 | 142 | 0.450 |
Why?
|
| Proteomics | 5 | 2016 | 201 | 0.450 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 3 | 2001 | 9 | 0.450 |
Why?
|
| Rhabdomyosarcoma | 2 | 2022 | 43 | 0.440 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 164 | 0.440 |
Why?
|
| Algorithms | 4 | 2019 | 1811 | 0.430 |
Why?
|
| Oxidoreductases | 3 | 2001 | 109 | 0.430 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2022 | 126 | 0.410 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2022 | 42 | 0.410 |
Why?
|
| Information Dissemination | 4 | 2022 | 101 | 0.390 |
Why?
|
| Adolescent | 15 | 2023 | 8849 | 0.390 |
Why?
|
| 3-Iodobenzylguanidine | 2 | 2021 | 19 | 0.390 |
Why?
|
| Loss of Heterozygosity | 2 | 2014 | 85 | 0.390 |
Why?
|
| Machine Learning | 3 | 2022 | 218 | 0.380 |
Why?
|
| Pharmacogenetics | 3 | 2019 | 426 | 0.370 |
Why?
|
| Child, Preschool | 12 | 2022 | 3578 | 0.370 |
Why?
|
| Computational Biology | 2 | 2015 | 527 | 0.360 |
Why?
|
| Isotope Labeling | 1 | 2009 | 50 | 0.360 |
Why?
|
| Databases, Protein | 1 | 2009 | 52 | 0.350 |
Why?
|
| Young Adult | 11 | 2023 | 5882 | 0.320 |
Why?
|
| N-Myc Proto-Oncogene Protein | 3 | 2017 | 36 | 0.320 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 2339 | 0.320 |
Why?
|
| Age Factors | 4 | 2021 | 1827 | 0.310 |
Why?
|
| Cohort Studies | 9 | 2021 | 2717 | 0.310 |
Why?
|
| Patient-Centered Care | 2 | 2023 | 198 | 0.310 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 447 | 0.300 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2667 | 0.270 |
Why?
|
| Acyl Coenzyme A | 2 | 2001 | 17 | 0.260 |
Why?
|
| Gene Amplification | 2 | 2017 | 131 | 0.260 |
Why?
|
| Proteins | 1 | 2009 | 762 | 0.240 |
Why?
|
| Eligibility Determination | 1 | 2023 | 31 | 0.240 |
Why?
|
| Oncogene Proteins | 2 | 2015 | 58 | 0.240 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 2 | 2000 | 10 | 0.240 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 249 | 0.230 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1894 | 0.230 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 1594 | 0.230 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 6 | 0.220 |
Why?
|
| Mutation | 4 | 2015 | 3904 | 0.220 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2022 | 47 | 0.220 |
Why?
|
| Genomics | 4 | 2022 | 690 | 0.220 |
Why?
|
| Chromatography, Liquid | 2 | 2015 | 103 | 0.210 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 2395 | 0.210 |
Why?
|
| Prognosis | 8 | 2021 | 3625 | 0.210 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 74 | 0.210 |
Why?
|
| Data Collection | 2 | 2023 | 363 | 0.210 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 303 | 0.210 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 104 | 0.210 |
Why?
|
| Arginine | 1 | 2001 | 136 | 0.200 |
Why?
|
| User-Computer Interface | 2 | 2019 | 185 | 0.200 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 1929 | 0.200 |
Why?
|
| Male | 15 | 2022 | 40457 | 0.200 |
Why?
|
| Female | 16 | 2021 | 43906 | 0.200 |
Why?
|
| Substrate Specificity | 1 | 2001 | 346 | 0.200 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.200 |
Why?
|
| Sarcoma | 1 | 2022 | 210 | 0.190 |
Why?
|
| Survivorship | 1 | 2020 | 17 | 0.190 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 21 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1262 | 0.180 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 104 | 0.180 |
Why?
|
| Myeloablative Agonists | 2 | 2016 | 34 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 2401 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 261 | 0.180 |
Why?
|
| Patient Selection | 1 | 2023 | 684 | 0.180 |
Why?
|
| Remote Sensing Technology | 1 | 2018 | 5 | 0.180 |
Why?
|
| Adult | 10 | 2022 | 25284 | 0.180 |
Why?
|
| Workflow | 1 | 2019 | 74 | 0.180 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 684 | 0.170 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 688 | 0.170 |
Why?
|
| Biomedical Technology | 1 | 2018 | 20 | 0.170 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 96 | 0.170 |
Why?
|
| Research | 1 | 2020 | 251 | 0.170 |
Why?
|
| Wearable Electronic Devices | 1 | 2018 | 23 | 0.170 |
Why?
|
| Smartphone | 1 | 2018 | 35 | 0.170 |
Why?
|
| Database Management Systems | 1 | 2018 | 41 | 0.160 |
Why?
|
| Survivors | 2 | 2016 | 221 | 0.160 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 386 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 176 | 0.160 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 25 | 0.160 |
Why?
|
| Coronary Care Units | 1 | 2016 | 4 | 0.150 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2016 | 35 | 0.150 |
Why?
|
| Buthionine Sulfoximine | 1 | 2016 | 7 | 0.150 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 45 | 0.150 |
Why?
|
| Survival Analysis | 3 | 2021 | 1535 | 0.150 |
Why?
|
| Mitochondria | 1 | 2000 | 525 | 0.140 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 136 | 0.140 |
Why?
|
| Caspase 10 | 1 | 2015 | 5 | 0.140 |
Why?
|
| Registries | 1 | 2020 | 691 | 0.140 |
Why?
|
| Melphalan | 1 | 2016 | 96 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2021 | 602 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 140 | 0.140 |
Why?
|
| Hydrazines | 1 | 2015 | 29 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 74 | 0.140 |
Why?
|
| Risk Factors | 7 | 2021 | 5310 | 0.140 |
Why?
|
| Proteome | 1 | 2016 | 120 | 0.140 |
Why?
|
| Carbohydrate Sequence | 1 | 2015 | 20 | 0.140 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2015 | 24 | 0.140 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 138 | 0.140 |
Why?
|
| Physician's Role | 1 | 2017 | 179 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2016 | 163 | 0.130 |
Why?
|
| Triazoles | 1 | 2015 | 96 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2021 | 2249 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2016 | 290 | 0.130 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2014 | 6 | 0.130 |
Why?
|
| Exome | 1 | 2015 | 125 | 0.130 |
Why?
|
| Glycosylation | 1 | 2015 | 128 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2016 | 673 | 0.130 |
Why?
|
| Anticoagulants | 2 | 2019 | 400 | 0.130 |
Why?
|
| Skull | 1 | 2016 | 249 | 0.130 |
Why?
|
| Oligopeptides | 1 | 2015 | 178 | 0.130 |
Why?
|
| Plasma Cells | 1 | 2015 | 80 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 236 | 0.130 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2014 | 46 | 0.130 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 23 | 0.130 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 3025 | 0.130 |
Why?
|
| Asthma | 1 | 2022 | 940 | 0.130 |
Why?
|
| Risk Assessment | 4 | 2022 | 2229 | 0.130 |
Why?
|
| Critical Illness | 1 | 2016 | 279 | 0.120 |
Why?
|
| Protein Conformation | 2 | 2011 | 879 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2016 | 284 | 0.120 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2014 | 112 | 0.120 |
Why?
|
| DNA Repair | 2 | 2016 | 353 | 0.120 |
Why?
|
| Neurocalcin | 1 | 2013 | 2 | 0.120 |
Why?
|
| Adenosine Triphosphatases | 1 | 2014 | 152 | 0.120 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2013 | 23 | 0.120 |
Why?
|
| Inpatients | 1 | 2016 | 286 | 0.120 |
Why?
|
| Sex Factors | 1 | 2016 | 1041 | 0.120 |
Why?
|
| Citric Acid | 1 | 2013 | 38 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2014 | 158 | 0.120 |
Why?
|
| Cell Separation | 1 | 2013 | 195 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 846 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 319 | 0.110 |
Why?
|
| Isovaleryl-CoA Dehydrogenase | 3 | 2001 | 3 | 0.110 |
Why?
|
| Heparin | 1 | 2013 | 174 | 0.110 |
Why?
|
| DNA Damage | 1 | 2014 | 361 | 0.110 |
Why?
|
| Enzyme Stability | 3 | 2001 | 38 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2014 | 328 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2016 | 868 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1196 | 0.110 |
Why?
|
| Middle Aged | 4 | 2019 | 24747 | 0.110 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2014 | 275 | 0.110 |
Why?
|
| Pelvic Neoplasms | 1 | 2012 | 44 | 0.110 |
Why?
|
| Acetylation | 1 | 2011 | 121 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6457 | 0.100 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2014 | 432 | 0.100 |
Why?
|
| Ubiquitin | 1 | 2011 | 90 | 0.100 |
Why?
|
| Methylation | 1 | 2011 | 243 | 0.100 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 329 | 0.100 |
Why?
|
| Time Factors | 2 | 2016 | 5181 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 740 | 0.100 |
Why?
|
| Gene Expression | 1 | 2015 | 1277 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 1204 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1651 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2014 | 534 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 723 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 755 | 0.090 |
Why?
|
| Precision Medicine | 3 | 2021 | 383 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 734 | 0.090 |
Why?
|
| Cell Cycle | 1 | 2011 | 502 | 0.090 |
Why?
|
| Erythrocyte Transfusion | 1 | 2010 | 58 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 530 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2009 | 63 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2009 | 105 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2009 | 49 | 0.090 |
Why?
|
| Ecosystem | 2 | 2023 | 310 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 100 | 0.090 |
Why?
|
| Isoantibodies | 1 | 2010 | 114 | 0.090 |
Why?
|
| Phosphorylation | 1 | 2011 | 1094 | 0.090 |
Why?
|
| Apoptosis | 1 | 2015 | 1669 | 0.090 |
Why?
|
| Autoantibodies | 1 | 2010 | 257 | 0.090 |
Why?
|
| Information Storage and Retrieval | 1 | 2009 | 119 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 187 | 0.080 |
Why?
|
| Cell Line | 2 | 2013 | 2452 | 0.080 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 124 | 0.080 |
Why?
|
| DNA, Neoplasm | 1 | 2009 | 266 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2009 | 142 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2022 | 2336 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2022 | 4090 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 385 | 0.080 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 1054 | 0.080 |
Why?
|
| Aged | 3 | 2019 | 18156 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2009 | 459 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2008 | 150 | 0.080 |
Why?
|
| Models, Molecular | 2 | 2001 | 1276 | 0.070 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 1069 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2013 | 1511 | 0.070 |
Why?
|
| Mice | 3 | 2016 | 11056 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2016 | 302 | 0.070 |
Why?
|
| Models, Biological | 1 | 2011 | 1732 | 0.060 |
Why?
|
| Research Design | 1 | 2008 | 582 | 0.060 |
Why?
|
| Genotype | 1 | 2009 | 1845 | 0.060 |
Why?
|
| Protein Binding | 2 | 2013 | 1439 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 71 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2022 | 130 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 69 | 0.050 |
Why?
|
| Africa | 1 | 2022 | 98 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2001 | 1009 | 0.050 |
Why?
|
| Energy Transfer | 1 | 2001 | 25 | 0.050 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2001 | 86 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 2329 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 1559 | 0.050 |
Why?
|
| Survival Rate | 2 | 2016 | 1852 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 318 | 0.050 |
Why?
|
| Mitotic Index | 1 | 2020 | 20 | 0.050 |
Why?
|
| Animals | 4 | 2016 | 26197 | 0.050 |
Why?
|
| Hemiterpenes | 1 | 2000 | 6 | 0.050 |
Why?
|
| Pentanoic Acids | 1 | 2000 | 6 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2001 | 337 | 0.050 |
Why?
|
| Leucine | 1 | 2000 | 66 | 0.050 |
Why?
|
| Mitosis | 1 | 2020 | 149 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2021 | 354 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 266 | 0.050 |
Why?
|
| United States | 2 | 2023 | 6473 | 0.050 |
Why?
|
| Open Reading Frames | 1 | 2000 | 117 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 414 | 0.040 |
Why?
|
| Biological Transport | 1 | 2000 | 394 | 0.040 |
Why?
|
| Warfarin | 1 | 2019 | 103 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 855 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 346 | 0.040 |
Why?
|
| Binding Sites | 1 | 2001 | 1083 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2016 | 7829 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2017 | 41 | 0.040 |
Why?
|
| Durapatite | 1 | 2016 | 30 | 0.040 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2016 | 7 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2016 | 77 | 0.040 |
Why?
|
| Caspase 8 | 1 | 2015 | 34 | 0.040 |
Why?
|
| Intracellular Space | 1 | 2015 | 37 | 0.040 |
Why?
|
| Glutathione | 1 | 2016 | 102 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 2057 | 0.040 |
Why?
|
| Proteasome Inhibitors | 1 | 2015 | 50 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 150 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 674 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2022 | 8150 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 703 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 71 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2015 | 54 | 0.030 |
Why?
|
| Bortezomib | 1 | 2015 | 74 | 0.030 |
Why?
|
| International Cooperation | 1 | 2015 | 126 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 290 | 0.030 |
Why?
|
| Thalidomide | 1 | 2015 | 52 | 0.030 |
Why?
|
| Pyrazines | 1 | 2015 | 84 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 306 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1041 | 0.030 |
Why?
|
| DNA, Fungal | 1 | 2014 | 57 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 128 | 0.030 |
Why?
|
| Computer Security | 1 | 2014 | 16 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2014 | 16 | 0.030 |
Why?
|
| Information Systems | 1 | 2014 | 28 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2015 | 285 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 171 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 689 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 455 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 1671 | 0.030 |
Why?
|
| Confidentiality | 1 | 2014 | 77 | 0.030 |
Why?
|
| SEER Program | 1 | 2014 | 184 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 148 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2015 | 322 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2013 | 48 | 0.030 |
Why?
|
| Internet | 1 | 2015 | 309 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1786 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 359 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2013 | 278 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 277 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 480 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 1504 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2013 | 609 | 0.030 |
Why?
|
| Phylogeny | 1 | 2016 | 1127 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2013 | 574 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 532 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1645 | 0.020 |
Why?
|
| Laryngeal Edema | 1 | 2010 | 7 | 0.020 |
Why?
|
| Hemagglutinins | 1 | 2010 | 19 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 695 | 0.020 |
Why?
|
| Acute Chest Syndrome | 1 | 2010 | 16 | 0.020 |
Why?
|
| Death, Sudden | 1 | 2010 | 40 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 928 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 631 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 157 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 1365 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 290 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2208 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 1132 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 2010 | 200 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 3598 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2013 | 1416 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 917 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1536 | 0.020 |
Why?
|
| Pneumonia, Viral | 1 | 2010 | 308 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 2845 | 0.010 |
Why?
|
| Mitochondria, Liver | 1 | 1998 | 27 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1998 | 106 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 392 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 1998 | 481 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1998 | 526 | 0.010 |
Why?
|
| Kinetics | 1 | 1998 | 1506 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1998 | 1205 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1998 | 591 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1998 | 723 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1998 | 2788 | 0.010 |
Why?
|
| Rats | 1 | 1998 | 3968 | 0.010 |
Why?
|